Finanzen von Oramed Pharmaceuticals Inc (ORMP)ORMPOramed Pharmaceuticals Inc

Evaluating the bottom line, Oramed Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 74.10%, provide a clear picture of how effectively ORMP converts its operational activities into shareholder value.

In the context of the broader market, ORMP competes directly with industry leaders such as OGCP and MDWD. With a market capitalization of $161.82M, it holds a significant position in the sector. When comparing efficiency, ORMP's gross margin of N/A stands against OGCP's N/A and MDWD's 10.90%. Such benchmarking helps identify whether Oramed Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has shown a significant turnaround with a net income of $78.16 million in Q2 2026, compared to losses in previous quarters. The gross margin is low, at 0.65%, but the recent profitability signals operational efficiency.